medigraphic.com
ISSN 2448-8011 (Electronic)
Revista de Divulgación del INSTITUTO DE MEDICINA FORENSE de la UNIVERSIDAD VERACRUZANA

2018, Number 2

<< Back Next >>

Rev Mex Med Forense 2018; 3 (2)

Usefulness of immunohistochemistry in the diagnosis of hepatocolangiocarcinoma

Mora-Morales E, Denis-Rodríguez PB, Melo SG, Aguirre GÁA

Language: Spanish
References: 10
Page: 47-53
PDF size: 321.92 Kb.


ABSTRACT

We present the case of a male individual, 67 years of age, with no relevant history, which presented a hepatic neoformation of 6 months of evolution. The preliminary histological interpretation was: Well-differentiated carcinoma, with 5% necrosis, 10% macrovesicular steatosis, 5% microvesicular steatosis and cirrhosis. In a complementary analysis, immunohistochemical studies were carried out to detect cytokeratin 19, cytokeratin 7, carcinoembryonic antigen and Heppar1, being positive to the 4 mentioned tumor markers. With this, the immunohistochemistry allowed us to make the diagnosis of a Hepatocellular Carcinoma combined with Cholangiocarcinoma, entities that are not usually associated; we perform an analysis of the immunohistochemical application in cases in which the histopathological analysis can be confusing.


REFERENCES

  1. Avilés A, Luévano A, Herrera R. Hepatocolangicarcinomacombinado. Presentación de un caso y revisión de la literatura. Rev Gastroenterol Mex. 2006; 71:483---6.

  2. Edmondson HA, Steiner P. Primary carcinoma of the liver: a study of 100 cases among 8,900 necropsies. Cancer. 1954; 7: 462-503.

  3. Gómez-Mateo M, Rodrigo B, Cabezas-Macián M. Hepatocolangiocarcinoma combinado. Claves para su diagnóstico anatomopatológico. Rev Esp Patol. 2013; 46: 73---8.

  4. Hatano H, Kobayashi S, Nagano H. A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus. Gan To Kagaku Ryoho. 2009; 36: 2374-6.

  5. Ikeda H, Harada K, Sato Y. Clinicopathologic significance of combined hepatocellularcholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol. 2013; 140:329-40.

  6. Paradis V. Histopathology of hepatocellular carcinoma. Recent Results Cancer Res. 2013; 190: 21-32.

  7. Tejeda AA, Cabrera MP, Martínez MS. Hepatocholangiocarcinoma in young patient with a giant liver tumour. Cirugía y Cirujanos, 2017; 85(3): 250-253.

  8. Willekens I, Hoorens A, Geers C. Combined hepatocellular and cholangiocellular carcinoma presenting with radiological characteristics of focal nodular hyperplasia. World J Gastroenterol. 2009; 15: 3940-3.

  9. Yano Y, Yamamoto J, Kosuge T. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol.2003; 33: 283---7.

  10. Zhou Y-M, Zhang X-F, Wu L-P. Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study. World J Gastroenterol. 2014; 20: 12615---20.




2020     |     www.medigraphic.com